G
GSK
Corporate · Founded 1891 · London, United Kingdom
GSK (GlaxoSmithKline) is a global healthcare company focused on improving the quality of human life by developing innovative medicines, vaccines, and consumer healthcare products. The company operates in three primary areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. GSK serves a wide range of clients, including patients, healthcare professionals, and governments worldwide. In the Pharmaceuticals segment, GSK researches and develops medicines to treat various diseases, including respiratory conditions, HIV, oncology, and immuno-inflammation. The Vaccines segment focuses on creating vaccines to prevent illnesses such as influenza, shingles, and COVID-19. The Consumer Healthcare division offers over-the-counter products for wellness, oral health, nutrition, and skin health. GSK operates in the highly competitive and regulated global healthcare market. The company’s business model revolves around extensive research and development (R&D) to bring new products to market. GSK invests heavily in scientific innovation to stay ahead of emerging health threats and meet the evolving needs of patients. GSK generates revenue primarily through the sale of its pharmaceutical products, vaccines, and consumer healthcare items. The company also collaborates with other biotech firms and governments, which can include agreements for the purchase of treatments, such as their COVID-19 therapy, sotrovimab. Additionally, GSK offers support programs to help patients afford their medications, ensuring broader access to their products. In summary, GSK is a science-led healthcare company dedicated to developing and delivering a wide range of innovative products that improve health outcomes globally. The company’s commitment to R&D, strategic partnerships, and patient support programs are key drivers of its growth and performance.
The funds GSK backs.
GSK is a limited partner in 14 funds. 2 of them place in the Power Law Investor Ranking, and the best-ranked are shown here.
GSK’s biggest exits.
Portfolio companies that IPO’d or were acquired at $1B+, with the valuation recorded at exit and — for those still public — their value today. Exit events come from each company’s funding-round history; entry stage from GSK’s transaction record.
Where GSK’s portfolio is concentrated.
Distribution of portfolio companies by headquarters country, sector, entry stage and current growth stage. Across all 29 portfolio companies. "Stage entered" is the first priced round the investor joined, derived from the investor’s transaction history.
-
USA14
-
UK8
-
Switzerland3
-
Canada1
-
China1
-
Denmark1
-
Germany1
-
Health28
-
Energy1
-
Series B+15
-
Series A8
-
Seed2
-
Late Growth18
-
Breakout Stage7
-
Early Growth3
-
Mature1
Inside GSK’s portfolio.
The 28 highest-funded portfolio companies, of 29 tracked.
Cu
23
Ap
Sp
Se
Ep
Li
At
De
An
Re
CR
As
Ou
Bi
Ch
Co
Ch
Si
Ne
Co
El
Se
Pa
Ca
Ha
Di
AdWhere GSK’s portfolio founders come from.
32 founders across the 29 highest-funded portfolio companies — by current location, university attended, and the companies they worked at before founding. Sourced from the founder records the API links to each portfolio company.
-
United States14
-
United Kingdom7
-
Switzerland3
-
Germany2
-
China1
-
Cuba1
-
India1
-
Sweden1
-
University of Cambridge4
-
Cornell University3
-
Massachusetts Institute of Technology3
-
University College London2
-
University of California, Berkeley2
-
Yale University2
-
Berlin University of Applied Sciences1
-
Bxscience1
-
Columbia University1
-
Duke University1
-
Juvenescence3
-
Andor Capital Management1
-
Anthem1
-
Apple Tree Partners1
-
Arsomedi1
-
Bayer CropScience1
-
Children’s Hospital Boston1
-
Cornell University1
-
Dana-Farber Cancer Institute1
-
EarSketch1
Other LPs.
Other corporate and insurance LPs in the Power Law LP ranking, closest to GSK by combined power-law score — Europe first, then the nearest worldwide.
Key people at GSK.




